Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
- PMID: 28634704
- DOI: 10.1007/s40618-017-0717-8
Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
Comment on
-
Teprotumumab for Thyroid-Associated Ophthalmopathy.N Engl J Med. 2017 May 4;376(18):1748-1761. doi: 10.1056/NEJMoa1614949. N Engl J Med. 2017. PMID: 28467880 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources